Adalta Ltd has released a press release.
AD-214 progress and priorities webinar presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from AdAlta
- Balance of R&D Tax Incentive Refund received
- 1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer
- R&D Tax Incentive Refund received
- Quarterly Appendix 4C and Activities Report
- AD-214 program update, cash runway extension
Later from AdAlta
- Second Japan patent for AD-214
- AdAlta welcomes new substantial shareholders
- Publication highlights I-body potential in osteoporosis
- Rights Offer to fund early return to clinic and growth
- AdAlta to support early return to clinical trials of AD-214 with rights offer
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta